Actuate Therapeutics Inc ACTU · Stock Open Actuate Therapeutics Inc in new tab
Actuate Therapeutics Inc Analysis (ACTU)
Is Actuate Therapeutics Inc a good investment? Actuate Therapeutics Inc (ACTU) is currently trading at 1.52 USD. Market analysts have a consensus price target of 9.98 USD. This suggests a potential upside from current levels.
Earnings Schedule: Actuate Therapeutics Inc is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is -0.85.
Investor FAQ
Does Actuate Therapeutics Inc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Actuate Therapeutics Inc?
Actuate Therapeutics Inc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -0.98.
Company Profile
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Community Discussion